PMID- 37023858 OWN - NLM STAT- MEDLINE DCOM- 20230522 LR - 20230610 IS - 2949-8759 (Electronic) IS - 2949-8767 (Print) IS - 2949-8759 (Linking) VI - 149 DP - 2023 Jun TI - Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080 MOMs study. PG - 209030 LID - S2949-8759(23)00080-2 [pii] LID - 10.1016/j.josat.2023.209030 [doi] AB - INTRODUCTION: Pregnant individuals with substance use disorders face complex issues that may serve as barriers to treatment entry and retention. Several professional organizations have established recommendations on comprehensive, collaborative approaches to treatment to meet the needs of this population, but information on real-world application is lacking. Sites participating in the NIDA CTN0080 "Medication treatment for Opioid use disorder in expectant Mothers (MOMs)"-a randomized clinical trial of extended release compared to sublingual buprenorphine among pregnant and postpartum individuals (PPI)-were selected, in part, because they have a collaborative approach to treating PPI with opioid use disorder (OUD). However, organizational differences among sites and how they implement expert recommendations for collaborative care could impact study outcomes. METHODS: Prior to study launch at each of the 13 MOMs sites, investigators used the Pregnancy and Addiction Services Assessment (PAASA) to collect information about organizational factors. Input from a team of addiction, perinatal, and economic evaluation experts guided the development of the PAASA. Investigators programmed the PAASA into a web-based data system and summarized the resultant site data using descriptive statistics. RESULTS: Study sites represented four US census regions. Most sites were specialty obstetrics & gynecology (OB/GYN) programs providing OUD services (n = 9, 69.2 %), were affiliated with an academic institution (n = 11, 84.6 %), and prescribed buprenorphine in an ambulatory/outpatient setting (n = 11, 84.6 %); all sites offered access to naloxone. Sites reported that their population was primarily White, utilized public insurance, and faced numerous psychosocial barriers to treatment. Although all sites offered many services recommended by expert consensus groups, they varied in how they coordinated these services. CONCLUSIONS: By providing the organizational characteristics of sites participating in the MOMs study, this report assists in filling the current gap in knowledge regarding similar programs providing services to PPI with OUD. Collaborative care programs such as those participating in MOMs are uniquely positioned to participate in research to determine the most effective models of care and to determine how research can be integrated into those clinical care settings. CI - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Kropp, Frankie B AU - Kropp FB AD - Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 3131 Harvey Avenue, Cincinnati, OH 45229, USA. Electronic address: frankie.kropp@uc.edu. FAU - Smid, Marcela C AU - Smid MC AD - University of Utah, 50 N. Medical Drive, Salt Lake City, UT 84132, USA. Electronic address: marcela.smid@hsc.utah.edu. FAU - Lofwall, Michelle R AU - Lofwall MR AD - Departments of Behavioral Science and Psychiatry, University of Kentucky College of Medicine, 845 Angliana Avenue, Lexington, KY 40508, USA. Electronic address: michelle.lofwall@uky.edu. FAU - Wachman, Elisha M AU - Wachman EM AD - Boston Medical Center, 801 Albany Street, Boston, MA 02119, USA. Electronic address: Elisha.Wachman@bmc.org. FAU - Martin, Peter R AU - Martin PR AD - Vanderbilt Psychiatric Hospital, Vanderbilt University Medical Center, 1601 23rd Avenue South, Suite 3035, Nashville, TN 372124, USA. Electronic address: peter.martin@vumc.org. FAU - Murphy, Sean M AU - Murphy SM AD - Department of Population Health Sciences, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA. Electronic address: smm2010@med.cornell.edu. FAU - Wilder, Christine M AU - Wilder CM AD - Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 3131 Harvey Avenue, Cincinnati, OH 45229, USA; Center for Addiction Research, University of Cincinnati College of Medicine, 3230 Eden Avenue, Cincinnati, OH 45267, USA. Electronic address: wildercn@ucmail.uc.edu. FAU - Winhusen, T John AU - Winhusen TJ AD - Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 3131 Harvey Avenue, Cincinnati, OH 45229, USA; Center for Addiction Research, University of Cincinnati College of Medicine, 3230 Eden Avenue, Cincinnati, OH 45267, USA. Electronic address: winhust@ucmail.uc.edu. LA - eng SI - ClinicalTrials.gov/NCT03918850 SI - ClinicalTrials.gov/NCT03911739 SI - ClinicalTrials.gov/NCT03911466 GR - U10 DA015831/DA/NIDA NIH HHS/United States GR - UG1 DA013732/DA/NIDA NIH HHS/United States GR - UG1 DA049444/DA/NIDA NIH HHS/United States GR - UG1 DA015831/DA/NIDA NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural DEP - 20230404 PL - United States TA - J Subst Use Addict Treat JT - Journal of substance use and addiction treatment JID - 9918541186406676 RN - 25081-31-6 (N-nitrosoiminodiacetic acid) RN - 40D3SCR4GZ (Buprenorphine) SB - IM MH - Pregnancy MH - Female MH - Humans MH - Mothers MH - Opiate Substitution Treatment MH - *Opioid-Related Disorders/drug therapy MH - *Buprenorphine/therapeutic use MH - Postpartum Period PMC - PMC10249488 MID - NIHMS1904508 OTO - NOTNLM OT - Collaborative care OT - Opioid use disorder OT - Organizational factors OT - Postpartum OT - Pregnant COIS- Declaration of competing interest Dr. Smid serves as a medical consultant for Gilead Science Inc. for hepatitis C treatment in pregnancy and Organon on postpartum hemorrhage management in a low resource setting. Her institution received funding from Alydia Health/Organon for research activities. She receives research support from the CDC and NIDA. Dr. Lofwall reports having consulted for Titan Pharmaceuticals Inc. and Camurus, and Dr. Murphy reports having consulted for Sandoz Inc., Nature Sacred Inc., and West Virginia Perinatal Partnership Inc. outside of the submitted work. All other authors have no potential conflicts of interest to report. EDAT- 2023/04/07 06:00 MHDA- 2023/05/22 06:42 PMCR- 2023/06/08 CRDT- 2023/04/06 19:24 PHST- 2022/08/22 00:00 [received] PHST- 2022/11/17 00:00 [revised] PHST- 2023/03/20 00:00 [accepted] PHST- 2023/05/22 06:42 [medline] PHST- 2023/04/07 06:00 [pubmed] PHST- 2023/04/06 19:24 [entrez] PHST- 2023/06/08 00:00 [pmc-release] AID - S2949-8759(23)00080-2 [pii] AID - 10.1016/j.josat.2023.209030 [doi] PST - ppublish SO - J Subst Use Addict Treat. 2023 Jun;149:209030. doi: 10.1016/j.josat.2023.209030. Epub 2023 Apr 4.